Regional Analysis of Telavancin and Comparator Antimicrobial Activity against Multidrug-Resistant Staphylococcus aureus Collected in the United States from 2014 through 2016.
The in vitro antimicrobial activities of telavancin and comparator antimicrobials were evaluated against recent Staphylococcus aureus clinical isolates collected in the United States (USA). A total of 15,882 S. aureus isolates were collected (2014 through 2016) as part of the SENTRY Antimicrobial Surveillance Program from sites located in all US Census Bureau divisions. Broth microdilution MIC values were measured using current reference methods. Data were stratified by year and by census division, and resistance rates were analysed for significant trends. Previously published data on methicillin-resistant S. aureus (MRSA) and multidrug-resistant (MDR) MRSA isolates (collected 2011 through 2013) were merged with the current isolate set to examine longer term resistance trends. Telavancin antimicrobial activity against MRSA and MDR MRSA isolates (MIC50/90 values, 0.03/0.06 µg/ml for both subsets) remained unchanged over the 3-year surveillance period, and all isolates were susceptible to telavancin. No difference in telavancin activity was noted when MIC data were stratified by year or by US Census Bureau division. When merged data (2011 through 2016) were analysed, the MRSA rate decreased for the entire USA and 6 individual census divisions, although the overall rate remained considerable. The overall US MDR MRSA rate also remained considerable and was unchanged from 2011 through 2016. The sustained potent activity of telavancin against US S. aureus isolates (100% susceptible) and the high rates of MRSA and MDR MRSA in the USA support the continued use of telavancin to treat indicated serious infections caused by S. aureus.